Success Story: EB-1A Approval in 1 Month for a Biotechnology Researcher Advancing Immunology and Translational Medicine
Client’s Testimonial:
"I can’t express enough gratitude/appreciation for all your help in getting both my NIW/EB-1A through the approval. Thank you so much!”
On June 15th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Research Associate in the Field of Biotechnology (Approval Notice).
General Field: Biotechnology
Position at the Time of Case Filing: Senior Research Associate
Country of Origin: China
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: June 15th, 2026
Processing Time: 1 month (Premium Processing Requested)
Case Summary:
The case centered on the client’s sustained achievements in immunology, translational medicine, and the evaluation of biotechnology developments. The petition explained how the client’s work has advanced the understanding of immune-mediated inflammatory responses, virus-induced malignancies, and critical cellular signaling pathways in aggressive hematological cancers. North America Immigration Law Group organized the case around a clear pattern of influence, showing how the client’s findings were used by other researchers to study inflammatory disease, cancer progression, leukemia biology, and therapeutic mechanisms.
The evidence showed that the client had authored 7 peer-reviewed journal articles, with publications appearing in highly regarded venues. Two of the client’s papers ranked among the top 10% of most-cited papers in Biology & Biochemistry for their respective publication years.
The petition also emphasized the international reach of the client’s work. The client’s publications had been cited more than 200 times by researchers in at least 34 countries, reflecting broad reliance on their findings across the biotechnology field. Independent researchers relied on the client’s work to investigate immunological signaling mechanisms, pathways regulating neuroinflammation, the mechanics of solid tumor and hematological cancer progression, and the critical role of cellular stress and protein homeostasis in oncogenesis and stem cell biology.
Additional evidence further demonstrated the client’s standing in the field. The client completed at least 24 peer reviews for journals. The case was also supported by 5 recommendation letters, and evidence that the client’s research had received funding support from organizations such as the National Institutes of Health, the National Natural Science Foundation of China, the American Cancer Society, and the National Program on Key Basic Research Projects.
This approval reflects the successful presentation of an EB-1A case built around sustained scientific influence, independent reliance, peer trust, and the practical value of biotechnology research. We congratulate the client on this important approval and are honored that North America Immigration Law Group could help demonstrate how their work continues to contribute to immunology, translational medicine, cancer research, and biotechnology development in the United States.